We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
R. Jeffrey Bailly: Thank you, Ron, and thank you to everyone joining the call. UFP had a strong second quarter. Revenue from our two largest customers, Intuitive Surgical and Stryker, grew 10% and 567%, respectively.
Why Intuitive Surgical stock is drawing attention now Intuitive Surgical (ISRG) is back in focus after a choppy stretch for the stock, prompting investors to reassess how its current share price lines up with recent returns and the scale of its surgical robotics business. See our latest analysis for Intuitive Surgical. At a share price of US$457.78, Intuitive Surgical has seen a 1-day share price return close to flat, a 7-day share price return of a 2.8% decline, and a year-to-date share...
Intuitive Surgical, Inc. (NASDAQ:ISRG) was among the stocks Jim Cramer highlighted, as he discussed the massive AI infrastructure buildout. A caller asked for Cramer’s thoughts on the company, and he said: Here’s the thing: Both J&J and Medtronic claim they’ve got competitors. And I am worried that one of those two is going to hit […]
Intuitive Surgical makes surgical robots, but that's not how it makes most of its money.
Intuitive Surgical (NASDAQ:ISRG) stockholders voted to approve all four proposals presented at the company’s 2026 Annual Meeting of Stockholders, which was held virtually, according to meeting remarks led by Gary Loeb, executive vice president and chief legal and compliance officer. Annual meeting
Intuitive Surgical faces mixed international trends as China pressure and Japan delays cloud otherwise strong OUS growth outlook.
Intuitive Surgical’s first quarter results for 2026 exceeded Wall Street’s expectations, with management crediting the outcome to strong global procedure growth and expansion of the da Vinci and Ion platforms. CEO David Rosa pointed to a 17% increase in total procedures, including “broad-based adoption across da Vinci and Ion as customers continue to advance minimally invasive care.” The company also highlighted notable gains in after-hours and non-urology procedures, as well as expanding uptake
Intuitive Surgical (ISRG) possesses solid growth attributes, which could help it handily outperform the market.